; it remains to be determined whether it also suppresses MCP-1 production. Monocyte chemoattractant protein 1 plays a significant role in the recruitment of monocytes and lymphocytes to the site of cellular immune reactions. In this study, we investigated whether PGE 2 downregulates polyI:C-induced MCP-1 production.
All experiments were conducted in accordance with the principles set forth in the Declaration of Helsinki. Enzymelinkedimmunosorbentassayandquantitativereal-timepolymerase chain reaction were performed with primary human conjunctivalepithelialcellsandimmortalizedhumancorneallimbal epithelial cells using previously described methods (eAppendix, http://www.archophthalmol.com). 3 First, we examined whether PGE 2 downregulated the production and messenger RNA (mRNA) expression of MCP-1 induced by polyI:C stimulation in human conjunctival and corneal epithelial cells. We found that it significantly attenuated the production of MCP-1 (Figure,  A) . Quantitative real-time polymerase chain reaction confirmed that the mRNA expression of MCP-1 was significantly downregulated by PGE 2 (Figure, A) .
Next, we examined which PGE 2 receptor(s) contributed to the downregulation of polyI:C-induced MCP-1. We used the EP 2 agonist ONO-AE-259, the EP 3 agonist ONO-AE-248, and the EP 4 agonist ONO-AE-329. Enzyme-linked immunosorbent assay showed that the EP 2 and EP 3 agonists significantly suppressed the polyI:Cinduced production of MCP-1, while the EP 4 agonist did not exert suppression (Figure, B) . Quantitative realtime polymerase chain reaction confirmed that the EP 2 and EP 3 agonists significantly downregulated the mRNA expression of MCP-1 (Figure, C) . Thus, our results document that PGE 2 attenuated the mRNA expression and production of MCP-1 via both EP 2 and EP 3 .
In human macrophages, PGE 2 attenuated the lipopolysaccharide-induced mRNA and protein expression of chemokines including MCP-1 through EP 4 . 6 On the other hand, we demonstrated that in human ocular surface epithelial cells, PGE 2 attenuated the polyI:C-induced mRNA and protein expression of MCP-1 through EP 2 and EP 3 but not EP 4 . Our findings suggest that EP 2 and EP 3 play important roles in the regulation of inflammation in epithelial cells, while EP 2 and EP 4 have important roles in immune cells such as macrophages.
In the tears and serum of patients with acute-stage Stevens-Johnson syndrome or toxic epidermal necrolysis, the levels of IL-6, IL-8, and MCP-1 were dramatically increased.
1 Although IL-8 was not regulated by PGE 2 , IL-6 was regulated by PGE 2 via EP 3 in human ocular surface epithelial cells. 3 Herein, we demonstrated that MCP-1 could be regulated by PGE 2 via EP 2 and EP 3 . The regulation of cytokine production by PGE 2 may be associated with the pathogenesis of Stevens-Johnson syndrome or toxic epidermal necrolysis with severe ocular complications because it was associated with polymorphism of the EP 3 gene (PTGER3), one of the PGE receptors (EP 1 , EP 2 , EP 3 , EP 4 ). 2 In summary, our results show that MCP-1 produced by human ocular surface epithelial cells could be downregulated by PGE 2 via EP 2 and EP 3 .
jiicho, Hirokoji, Kawaramachi, Kamigyoku, Kyoto 602-0841, Japan (mueta@koto.kpu-m.ac.jp). Author Contributions: Dr Ueta had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Financial Disclosure: The work described in this article was carried out in collaboration with Ono Pharmaceutical Co Ltd, who supplied ONO-AE-248 used in this study. Prostaglandin E 2 (PGE 2 ) attenuated the messenger RNA (mRNA) expression and production of monocyte chemoattractant protein 1 via both prostaglandin E receptor 2 (EP 2 ) and EP 3 . A, Primary human conjunctival epithelial cells (PHCjE) and human corneal-limbal epithelial cells (HCLE) were exposed to 10 µg/mL of polyinosine-polycytidylic acid (polyI:C) and 100 µg/mL of PGE 2 for 24 hours (enzyme-linked immunosorbent assay) or 6 hours (quantitative real-time polymerase chain reaction). GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase. B and C, The PHCjE and HCLE were exposed to 10 µg/mL of polyI:C and 10 µg/mL of the EP 2 , EP 3 , or EP 4 agonist for 24 hours (enzyme-linked immunosorbent assay) (B) or 6 hours (quantitative real-time polymerase chain reaction) (C). Data are representative of 3 separate experiments and are given as the mean (SEM) from 1 experiment carried out in 6 to 8 wells (enzyme-linked immunosorbent assay) (B) or 4 to 6 wells (quantitative real-time polymerase chain reaction) (C) per group. 
Depth Profile Study of Abnormal Collagen Orientation in Keratoconus Corneas
I n a previous study, 1 we used femtosecond laser technology to cut ex vivo human corneas into anterior, mid, and posterior sections, after which x-ray scatter patterns were obtained at fine intervals over each specimen. Data analysis revealed the predominant orientation of collagen at each sampling site, which was assembled to show the variation in collagen orientation between central and peripheral regions of the cornea and as a function of tissue depth. We hypothesized that the predominantly orthogonal arrangement of collagen (directed toward opposing sets of rectus muscles) in the mid and posterior stroma may help to distribute strain in the cornea by allowing it to withstand the pull of the extraocular muscles. It was also suggested that the more isotropic arrangement in the anterior stroma may play a role in tissue biomechanics by resisting intraocular pressure while at the same time maintaining corneal curvature. This article, in conjunction with our findings of abnormal collagen orientation in full-thickness keratoconus corneas, 2,3 received a great deal of interest from the scientific community and prompted the following question: how does collagen orientation change as a function of tissue depth when the anterior curvature of the cornea is abnormal, as in keratoconus? Herein, we report findings from our investigation aimed at answering this question.
Methods.
The Baron chamber used in our previous study 1 was adapted to enable corneal buttons to be clamped in place and inflated (by pumping physiological saline into the posterior compartment) to restore their natural curvature. A button diameter of 8 mm or larger was deemed necessary to ensure tissue stability during this process.
The next step, obtaining fresh, full-thickness, keratoconus buttons of sufficient diameter, proved to be problematic owing to the increasing popularity of deep anterior lamellar keratoplasty. Recently, however, the opportunity arose to examine an 8-mm full-thickness (300-340 µm minus epithelium) keratoconus corneal button with some central scarring and a mean power greater than 51.8 diopters (Figure 1) . The tissue was obtained in accordance with the tenets of the Declaration of Helsinki and with full informed consent from a 31-year-old patient at the time of penetrating keratoplasty. Using techniques detailed previously, 1 the corneal button was clamped in the chamber and inflated. The central 6.3-mm region of the button was then flattened by the applanation cone and a single cut was made at a depth of 150 µm from the surface using an IntraLase 60-kHz femtosecond laser (Abbott Medical Optics Inc), 1 thus splitting the cornea into anterior and posterior sections of roughly equal thickness. Wide-angle x-ray scattering patterns were collected at 0.25-mm intervals over each cor- 
